Imsidolimab
As of the edition of 20 October 2026, Imsidolimab is an antibody: stopped in 2024; acts on IL1RAP and IL1RL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 8, 3 stopped early
- Disease areas
- Skin and connective tissue; Infections; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 4 | 0 | 2 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vanda Pharmaceuticals | Lead sponsor of trials | 2019 to now |